Rhabdomyolysis

Published on 10/02/2015 by admin

Filed under Emergency Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1496 times

169 Rhabdomyolysis

DefinItion and Epidemiology

Rhabdomyolysis is a condition characterized by injury to skeletal muscle that results in release of the intracellular contents into the extracellular fluid and circulation. Authoritative thresholds for creatine kinase (CK) range between 1000 and 10,000 U/L, but some definitions additionally mandate the presence of myoglobinuria (Box 169.1).

Rhabdomyolysis can occur secondary to trauma, exertion, muscle hypoxia, genetic defects, infections, changes in body temperature, metabolic and electrolyte disorders, drugs and toxins, and idiopathic causes. Various categorizations of rhabdomyolysis have been proposed: traumatic versus atraumatic, reversible versus irreversible, endogenous versus exogenous, and hereditary versus acquired. More than half of all cases of rhabdomyolysis are multifactorial (Box 169.2).

Box 169.2 Causes of Rhabdomyolysis

Rhabdomyolysis afflicts more than 25,000 individuals in the United States each year. Morbidity and mortality vary tremendously depending on etiology, available treatment, time course, and comorbid factors. Acute kidney injury is a potential major complication of rhabdomyolysis and worldwide occurs in 15% to 45% of cases. In contrast, 7% to 10% of cases of acute kidney injury in the United States are caused by rhabdomyolysis.1 Mortality generally ranges from 3% to 10% but can be as high as 25% in mass casualty incidents that involve crush injuries.

Certain populations appear to be at increased risk for the development of rhabdomyolysis. Alcohol and recreational drug abusers, patients taking numerous medications, military recruits, and athletes training well above their level of conditioning are of particular concern. Athletes with a predominance of type II fast twitch fibers (typically sprinters and weight lifters) are at higher risk for rhabdomyolysis than are those with a majority of type I slow twitch fibers (e.g., marathon runners). A large number of genetic disorders are linked to rhabdomyolysis as well.

Causes of Rhabdomyolysis

Medical Decision Making and Diagnostic Testing

Urinalysis

The urine dipstick is a commonly used screening test for rhabdomyolysis. The orthotoluidine test on the urine dipstick will react in the presence of either myoglobin or hemoglobin. A report of “large blood” on the urine dipstick and absence of red blood cells on microscopy classically suggests the presence of free myoglobin in urine. Figure 169.1 shows the typical urine appearance in the setting of myoglobinuria. Unfortunately, clinical data do not fully support this screening practice, with microscopic hematuria occurring in about 30% of patients with rhabdomyolysis. In addition, myoglobinuria may be transient and not identified at the time of urinalysis despite the presence of significant clinical rhabdomyolysis. Dipstick testing will detect a urine myoglobin level higher than 1.0 mg/dL, which correlates with a serum value of approximately 100 mg/dL.

image

Fig. 169.1 Myoglobinuria.

The dipstick is strongly positive for blood, with no red blood cells seen on microscopy.

(From Roberts JR, Hedges JR. Clinical procedures in emergency medicine. 5th ed. Copyright 2009 Saunders, an imprint of Elsevier.)

Other common findings on urinalysis include the presence of tubular casts, proteinuria, and evidence of acute tubular necrosis.

Complications

Following sufficient muscle damage, extrusion of cellular contents into the general circulation causes several complications, including acute renal failure, metabolic derangements, DIC, compartment syndrome, and peripheral neuropathy.

Metabolic and Electrolyte Derangements

Hyperkalemia occurs in 10% to 40% of patients with rhabdomyolysis. It is the most serious electrolyte derangement observed with rhabdomyolysis because of its potential lethal effect on cardiac rhythm and function. More than 15 mmol of potassium is released with necrosis of only 150 g of muscle and results in an acute 1.0-mmol/L increase in extracellular potassium. The degree of increase is further dependent on renal function, which is often concurrently impaired.

Hypocalcemia is the most common metabolic complication of rhabdomyolysis; low calcium levels are present early and are usually asymptomatic. Hypocalcemia results from deposition of calcium salts in necrotic muscle secondary to hypophosphatemia and decreased 1,25-dihydroxycholecalciferol. Soft tissue calcifications can be seen on radiographs of the involved limbs. Hypocalcemia should be treated only if severe symptoms or hyperkalemia develops and leads to cardiac arrhythmias, muscular contraction, and seizures. Later, as calcium is mobilized from tissues, serum calcium levels rise and symptomatic hypercalcemia may develop. Hypercalcemia usually occurs in patients with acute renal failure during the diuretic phase, typically when urinary output is greater than 1500 mL/24 hr. Hypercalcemia also occurs more frequently if Ca2+ is supplemented in the hypocalcemic stage. Volume expansion alone is usually adequate treatment, but diuretics may be needed.

Hyperphosphatemia is caused by leakage of phosphate from injured myocytes and is higher in azotemic patients. Phosphate binders should be used when phosphate levels exceed 7 mg/dL. Hypophosphatemia may be seen later in the disease course but rarely requires treatment. Hypermagnesemia may occur in patients with renal insufficiency. Standard management is appropriate. Hyperuricemia is especially common in crush injury as a result of the release of muscle adenosine nucleotides, which are subsequently converted to uric acid in the liver. Uric acid levels typically correlate with serum CK levels.

Organic acids, especially lactic acid, are released from hypoxic, necrotic muscle cells and produce a pronounced anion gap acidosis.

Compartment Syndrome

Most striated muscles are contained within rigid compartments formed by fascia and bones. When the muscle is traumatized, marked swelling and edema occur within a closed osteofascial compartment, and muscle perfusion is reduced to a level below that required for cellular viability. As intracompartmental pressure rises above 30 to 35 mm Hg, compartment syndrome develops and significant muscle ischemia ensues and requires decompressive fasciotomy. Figure 169.2 shows an example of compartment syndrome.

Classic signs and symptoms of compartment syndrome include pain, pallor, paresthesias, poikilothermia, paralysis, and pulselessness. Paresthesias are the most reliable sign—muscle edema exerts pressure on peripheral nerves, which results in neuronal ischemia, paresthesias, and paralysis. Decompressive fasciotomy reverses the peripheral neuropathies within a few days to weeks, although symptoms may be permanent in a minority of patients.

Treatment

General Measures

Rhabdomyolysis is physiologically and clinically similar to cell degradation states such as tumor lysis syndrome and sepsis. An organized, aggressive treatment strategy should focus on clinical end points similar to those for other cell lysis conditions. The emergency treatment of rhabdomyolysis, in an early goal-directed fashion, is summarized in Figure 169.3.

The main goal of therapy is prevention of acute renal failure through high-volume resuscitation.4 The two most common reasons for the development of acute kidney injury are slow fluid resuscitation and inadequate fluid resuscitation. Normal saline is superior to lactated Ringer solution for the treatment of rhabdomyolysis because normal saline is not associated with risk for phosphate toxicity. More than 10 L of normal saline is typically administered in the first 24 hours of therapy to maintain high-volume dilute urine output.

Initial fluid administration with normal saline is titrated to achieve a goal urine output of 200 to 300 mL/hr. It is important that intravenous (IV) fluid resuscitation be started as soon as possible; fluid resuscitation before the extrication of crushed and trapped patients is preferred. After diuresis is established and urine pH is less than 6.5, fluids are changed to a more alkaline solution (i.e., 75 mmol of sodium bicarbonate added to 1 L of one-half isotonic saline), with the rate titrated to achieve the goal of 200 to 300 mL/hr of urine output. Alternating normal saline with sodium bicarbonate is also an option. If urine pH is higher than 6.5, normal saline is continued. Mannitol, an osmotic diuretic, can be considered in this situation, but only after adequate fluid repletion has been attained.

With moderate to severe alkalemia (serum pH higher than 7.5), acetazolamide can be considered. The goal urine output remains 200 to 300 mL/hr. Fluid repletion is continued until the CK level falls below 5000 to 10,000 U/L and the myoglobinuria clears.

If initial diuresis is not achieved with fluid replacement alone or the patient has contraindications to further fluid replacement, additional diuretics should be considered and a nephrologist consulted for possible renal replacement therapy.

Vital signs, cardiac rhythm, and urine output should be monitored continuously. Medication dosages should be adjusted according to renal function, and drugs that are potentially nephrotoxic should be avoided.

Pharmacologic Therapy

Avoid Calcium Supplementation and Loop Diuretics

Patients with rhabdomyolysis often have acute hypocalcemia. The hypocalcemia results from deposition of calcium salts in necrotic muscle. Supplemental calcium administration should be avoided if possible because it can exacerbate the cytoplasmic injury. During the rebound and recovery phases of rhabdomyolysis, calcium is remobilized and hypercalcemia becomes a true risk. Only if the patient is symptomatic or if severe hyperkalemia is present should calcium be considered, and even then other measures to ameliorate the hyperkalemia should be undertaken first.

Loop diuretics (e.g., furosemide) should generally be avoided because they contribute to urine acidification and tubular cast formation. Forced diuresis is best facilitated with mannitol. Under alkalemic conditions, acetazolamide can be considered.

Crush Syndrome: Disaster and Mass Casualty Considerations

Delayed extrication from debris causes delayed resuscitation—rhabdomyolysis and crush syndrome often emerge as the leading causes of delayed mortality. Crush syndrome, perhaps the most dramatic manifestation of rhabdomyolysis, results from both the initial blunt force trauma and the marked reperfusion injury that occurs after release of the crushing pressure. Commonly, crush syndrome will occur epidemically because of structural failure from earthquakes or warfare with resultant entrapment of victims beneath debris. Although acute renal failure is the most life-threatening manifestation, crush syndrome can occur with failure of any organ system, much like rhabdomyolysis. Frequently, management of the obvious concomitant traumatic injuries can overshadow the emergency of crush syndrome.

Crush syndrome and compartment syndrome act synergistically on the degradation of muscle. Acute musculoskeletal compartment syndrome can damage myocytes and induce rhabdomyolysis. Rhabdomyolysis in turn exacerbates the inflammatory cascade associated with crushing of the muscle compartment, thereby worsening compartment pressures. Crush syndrome may worsen acute renal failure.

During mass casualty situations in which crush injuries would be expected (earthquakes, building collapse, bombings), it is important to start IV volume restoration in all survivors as quickly as possible (see the Tips and Tricks box “Management of Crush Syndrome”). Emergency medical service and ED personnel should be instructed to begin IV resuscitation even before the victims have actually been extricated from the scene. This may involve placing an IV line in a confined space on any free limb.

The International Society of Nephrology can be contacted to respond to a mass casualty incident with emergency renal therapy equipment through its Disaster Relief Task Force (http://www.isn-online.org/isn/society/about/isn_20011.html).

References

1 Antons KA, Williams CD, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400–409.

2 Bosch X, Poch E, Grau J. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361:62–72.

3 Capacchione JF, Muldoon SM, et al. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg. 2009;109:1065–1069.

4 Chatzizisis YS, Misirli G, Giannoglou GD. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19:568–574.

5 Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678–685.

6 Karajala VW, Mansour W, Kellum JA. Diuretics in acute kidney injury. Minerva Anestesiol. 2009;75:251–257.

7 Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67:272–283.

8 Koyner JL, Sher Ali R, Murray PT. Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp Nephrol. 2008;109(4):e109–e117.

9 Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005;293:2918–2924.

10 Mannix RM, Tan ML, Wright R, et al. Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics. 2006;118:2119–2125.

11 McClure DL, Valuck RJ, Glanz M, et al. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf. 2007;16:132–143.

12 Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care. 2005;9:141–142.

13 Patel DR, Gysmfi R, Torres A. Exertional rhabdomyolysis and acute kidney injury. Physician Sportsmed. 2009;37:71–79.

14 Rodríguez-Capote K, Balion CM, Hill SA, et al. Utility of urine myoglobin for the prediction of acute renal failure in patients with suspected rhabdomyolysis: a systematic review. Clin Chem. 2009;55:2190–2197.

15 Sever MS, Lameire N, Vanholder R. Renal disaster relief: from theory to practice. Nephrol Dial Transplant. 2009;24:1730–1735.

16 Vanholder R, Van Biesen W, Lameire N, et al. The role of the International Society of Nephrology/Renal Disaster Relief Task Force in the rescue of renal disaster victims. Contrib Nephrol. 2007;156:325–332.

17 Walsh S, Fan SL. Visualising rhabdomyolysis. Lancet. 2009;373:154.

18 Alpers JP, Jones LK, Jr. Natural history of exertional rhabdomyolysis: a population-based analysis. Muscle Nerve. 2010;42:487–491.

19 Thondebhavi Subbaramaiah M, Sapsford D, Banham-Hall E. Acetazolamide as an adjunct to sodium bicarbonate in the treatment of rhabdomyolysis. Anaesth Intensive Care. 2010;38:398.

20 Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48:749–756.

21 Lai CC, Wang CY, Lin HI. Rhabdomyolysis and acute kidney injury associated with 2009 pandemic influenza A (H1N1). Am J Kidney Dis. 2010;55:615.

22 Hedenmalm K, Alvan G, Ohagen P, et al. Muscle toxicity with statins. Pharmacoepidemiol Drug Saf. 2010;19:223–231.

23 Young SE, Miller MA, Docherty M. Urine dipstick testing to rule out rhabdomyolysis in patients with suspected heat injury. Am J Emerg Med. 2009;27:875–877.

24 Lee PJ, Lachmann RH. Acute presentations of inherited metabolic disease in adulthood. Clin Med. 2008;8:621–624.

25 Clarkson PM. Exertional rhabdomyolysis and acute renal failure in marathon runners. Sports Med. 2007;37:361–363.

26 Hoffman JD, Steiner RD, Paradise L, et al. Rhabdomyolysis in the military: recognizing late-onset very long-chain acyl Co-A dehydrogenase deficiency. Mil Med. 2006;171:657–658.

27 Clarkson PM, Kearns AK, Rouzier P, et al. Serum creatine kinase levels and renal function measures in exertional muscle damage. Med Sci Sports Exerc. 2006;38:623–627.

28 Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337–343.

29 Linares LA, Golomb BA, Jaojoco JA, et al. The modern spectrum of rhabdomyolysis: drug toxicity revealed by creatine kinase screening. Curr Drug Saf. 2009;4:181–187.

30 Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4 methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol. 2008;3:1852–1860.

31 Silva M, Matthews ML, Jarvis C, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253–260.

32 Peltonen S, Ahlström A, Kylävainio V, et al. The effect of combining intermittent hemodiafiltration with forced alkaline diuresis on plasma myoglobin in rhabdomyolysis. Acta Anaesthesiol Scand. 2007;51:553–558.

33 Hatamizadeh P, Najafi I, Vanholder R, et al. Epidemiologic aspects of the Bam earthquake in Iran: the nephrologic perspective. Am J Kidney Dis. 2006;47:428–438.

34 Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma. 2004;56:1191.

35 Gonzalez D. Crush syndrome. Crit Care Med. 2005;33(1 Suppl):S34–S41.

36 Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982;61:141–152.

37 Allison RC, Bedsole DL. The other medical causes of rhabdomyolysis. Am J Med Sci. 2003;326:79–88.

38 Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med. 1990;322:825–829.

39 Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med. 1984;144:277–280.

40 Bywaters E, Beall D. Crush injuries with impairment of renal function. Br Med J. 1941;1:427–432.

41 Lippi G, Cervellin G, Comelli I. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48:749–756.

42 Fernandez WG, Hung O, Bruno GR, et al. Factors predictive of acute renal failure and need for hemodialysis among ED patients with rhabdomyolysis. Am J Emerg Med. 2005;23:1–7.

43 Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: complications and treatment. Eur J Intern Med. 2008;19:568–574.

44 Gunal AI, Celiker H, Dogukan A, et al. Early and vigorous fluid resuscitation prevents acute renal failure in crush victims of catastrophic earthquakes. J Am Soc Nephrol. 2004;15:1862–7186.

45 Mullins RJ, Slater MS, Malinosk DJ. Crush injury and rhabdomyolysis. Crit Care Clin. 2004;20:171–192.